Alatrofloxacin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alatrofloxacin
Alatrofloxacin.svg
Systematic (IUPAC) name
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a605016
Pregnancy cat. C (US)
Legal status Withdrawn
Routes Intravenous
Pharmacokinetic data
Bioavailability N/A
Protein binding 76% (trovafloxacin)
Metabolism Quickly hydrolyzed to trovafloxacin
Half-life 9 to 12 hours (trovafloxacin)
Excretion Fecal and renal (trovafloxacin)
Identifiers
CAS number 157182-32-6 N 157605-25-9
ATC code None
PubChem CID 5489474
ChemSpider 21106252 YesY
UNII 7QVV6I50DT YesY
ChEMBL CHEMBL1201197 N
Chemical data
Formula C26H25F3N6O5 
Mol. mass 558.509 g/mol
 N (what is this?)  (verify)

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 that encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

See also[edit]

References[edit]

  1. ^ "PubChem CID 5489474". 
  2. ^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. doi:10.1016/S0753-3322(03)00054-4. PMID 14568230. 
  3. ^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMC 1471980. PMID 16735322.